Session 201 | Neuropsychopharmacology of Autism Spectrum Disorders

Thursday, August 16, 2018
10:30am – 11:45am

Autism spectrum disorders (ASD) affect approximately 1 in 60 children and adolescents in the United States. Yet despite the profound impact these conditions have on individuals and their families, we still lack pharmacologic treatments to address the core symptoms (social function deficits and restrictive repetitive behaviors) or commonly associated features (intellectual disability and speech/language impairment).

Learning Objectives

After completing this activity, participants should be able to:

  • Describe the unmet need in medications to treat core autism symptoms.
  • Explain why large clinical trials have consistently produced negative results.
  • Identify the benefits and pitfalls of treating comorbidities.
  • Distinguish symptoms amenable to medications versus symptoms that require behavioral approaches.
  • Discuss current research targets oxytocin and arginine vasopressin.

Click HERE to go back to the Conference Agenda